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This article is a review of the therapeutic significance of arformoterol tartrate, a new generation β2 
adrenergic agonist bronchodilator available in a nebulized form. Arformoterol is well absorbed through 
the lungs when administered via a standard jet nebulizer and is useful in long-term maintenance therapy 
of bronchoconstriction in chronic obstructive pulmonary disease (COPD). Much clinical evidence 
suggest the potentially enhanced efficacy of this drug in the treatment of COPD including chronic 
bronchitis and emphysema. Various hyphenated analytical methodologies have also been employed for 
the determination and quantification of arformoterol. This review provides an updated account on the 
pharmacology, pharmacokinetics, clinical studies, analytical techniques, drug-drug interactions, 
contraindications, and therapeutic applications of arformoterol tartrate. 
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INTRODUCTION 
 
Global Initiative for Chronic Obstructive Lung 
Disease (GOLD) has defined chronic 
obstructive pulmonary disease (COPD) as a 
disease state characterized by airflow 
limitation that is not fully reversible. It is a 
progressive ailment generally associated with 
chronic reduced airflow, breathing difficulty, 
and pathologic pulmonary changes. It 
includes emphysema, an anatomically 
defined condition characterized by 
destruction and enlargement of the lung 
alveoli; chronic bronchitis which is a condition 
with chronic or recurrent excessive mucus 
secretion; and small airways disease, a 
condition in which small bronchioles are 
narrowed [1-4]. The characteristic symptoms 
of COPD are chronic and progressive 
dyspnea, cough, and sputum production. 
Chronic cough and sputum production may 
precede the development of airflow limitation. 
COPD is also characterized by various 
pathologic changes in proximal airways, 
peripheral airways, lung parenchyma, and 
pulmonary vasculature [5]. 
 
Most of the information available on COPD 
prevalence, morbidity and mortality comes 
from developed countries [6]. In 2000, over 
119,000 deaths in the United States and 2.74 
million deaths worldwide were attributed to 
COPD. Data from the National Health 
Interview Survey in 2001 indicates that 12.1 
million people over age 25 years in the 
United States had COPD. Over 9 million of 
these individuals had chronic bronchitis; the 
others had emphysema or a combination of 
both diseases [4]. A study conducted by the 
Global Burden of Disease under the auspices 
of the World Health Organization (WHO) and 
the World Bank concluded that the worldwide 
prevalence of COPD in 1990 was 9.34/1,000 
and 7.33/1,000 in men and women, 
respectively. The prevalence of this disease 
is highest in those countries where cigarette 
smoking is very common [6]. This disease 
accounted for 8 million medical outpatient 
visits, 1.5 million visits to emergency 
departments, and over 700,000 
hospitalizations in the year 2000 [7]. 
 
COPD is the fourth leading cause of death in 
the United States, exceeded only by cancer, 
heart disease and cerebrovascular accidents, 
accounting for 120,816 deaths in 2002 [4,7]. 
In the European Union, respiratory diseases 
accounted for a total direct cost of about 6 % 
of the total healthcare budget, with 56 % 
(€38.6 billion) of this expenditure due to 
COPD [5]. The reported physician-diagnosed 
COPD prevalence is approximately 10 million 
people in United States but nearly 24 million 
persons may have COPD as indicated by 
self-reporting surveys.  Compared to other 
common chronic diseases, the prevalence of 
COPD has steadily increased during the past 
30 years and it is estimated that by the year 
2020, it will become the third leading cause of 
death worldwide. In 2004, the economic 
impact of COPD was estimated at US$37.2 
billion, including over US$16 billion in indirect 
morbidity and mortality costs [4,7]. COPD 
was ranked sixth as the cause of death in 
1990 by the study projected by Global 
Burden of Disease [5].  
 
A variety of factors appear to increase the 
risk of developing COPD. These include 
asthma, air pollution, respiratory infections, 
chemicals, prenatal or childhood illness, 
nutrition and certain occupational dusts; of 
these, cigarette smoking remains the most 
important. Several investigation techniques 
for COPD includes the application of chest X-
ray, spirometry, helium dilution technique and 
computed tomography which allow the 
detection, characterization and diagnosis of 
this disease [8]. Table 1 summarizes the 
various stages of COPD severity. 
 
Inflammation of the airway wall is also 
associated with asthma. Increased number of 
various types of inflammatory cells, most 
notably eosinophils but also basophils, mast 
cells, macrophages, and certain types of 
lymphocytes, may be observed in airway 
walls [9]. 
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    Table 1: Various stages of COPD severity [1,2] 
 
Stage Stage 0 Stage I Stage II Stage III Stage IV 
Severity At risk 
 





























FEV1 : FVC 
 
> 0.7 ≤ 0.7 ≤ 0.7 ≤ 0.7 ≤ 0.7 

















Among the various therapeutic agents 
currently available for COPD, the focus of 
treatment is primarily on bronchodilators. 
Within this class, inhaled therapy is generally 
preferred over systemic therapy due to 
improved efficacy and favorable safety 
margins for additive benefits along with 
reduced side effects. Several options, 
including short- and long-acting inhaled β-
agonists, short and long acting inhaled 
anticholinergics, and methylxanthines exist 
for the treatment of COPD. Short-acting 
bronchodilators may be used for patients with 
mild disease but long-acting bronchodilators 
are more appropriate for patients with 
moderate to severe conditions. In general, β2-
agonists are in the broader class of 
sympathomimetic agents, which include 
agents that stimulate α, β1, and β2 receptors 
[7,8]. Compounds that are β2 selective are 
widely used to provide acute relief from 
airways obstruction in patients with asthma. 
Currently available β2 selective therapies are 
classified depending on the duration of 
action. These include albuterol, levalbuterol, 
pirbuterol, and terbutaline which act as short-
acting agents while long-acting agents 
include formoterol and salmeterol. However, 
the bronchoprotection afforded by short-
acting drugs persist for less than 3 - 4 h, so 
that it becomes necessary to use these drugs 
regularly to achieve symptomatic control. β2 
selective agonists with a longer  duration of 





Arformoterol (R,R-formoterol) is a active 
isomer of racemic formoterol and is indicated 
for the long-term, maintenance treatment of 
bronchoconstriction in patients with COPD 
including chronic bronchitis and emphysema. 
It is a new generation long-acting β2 
adrenergic agonist (LABA) bronchodilator for 
the treatment of COPD and is administered 
twice daily in the nebulized form. It is a potent 
and selective agent which causes bronchial 
smooth muscle relaxation and inhibits the 
release of inflammatory mediators. 
Arformoterol tartrate inhalation solution is a 
sterile, clear, colourless solution of the 
tartrate salt of arformoterol, the (R,R)-
enantiomer of formoterol. The chemical 
structure of arformoterol tartrate is depicted in 
Figure 1. The molecular weight of this drug is 
494.5 g/mol. It is a white to off white solid 
powder, slightly soluble in water [11,12]. 
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Arformoterol is a potent, selective, β2 
adrenergic agonist and long acting 
bronchodilator which acts in a way similar to 
that of other β2 adrenergic agonists such as 
formoterol and salmeterol. Its 
pharmacological effects can be attributed to 
the increased intracellular cyclic adenosine 
monophosphate (cAMP) levels that result 
from the stimulation of intracellular adenyl 
cyclase. Increased intracellular cAMP level 
causes relaxation of bronchial smooth 
muscles and inhibits the release of mediators 
of immediate hypersensitivity from cells, 




Arformoterol tartrate is well absorbed through 
lungs when administered by a nebulizer. The 
mean peak plasma concentration (Cmax) and 
systemic exposure (AUC0-12h) are 4.3 pg/mL 
and 34.5 pg.h/mL, respectively, when 15 µg 
arformoterol is administered every 12 h for 14 
days in COPD patients. The time to achieve 
median steady state peak plasma 
concentration (tmax) is approximately half an 
hour after drug administration. The mean 
terminal half-life is 26 h in COPD patients 
when treated with 15 µg inhaled arformoterol 
twice daily for 14 days. The binding of 
arformoterol to human plasma proteins in 
vitro is 52-65% at concentrations of 0.25, 0.5 
and 1.0 ng/mL of radiolabeled arformoterol. 
Metabolism occurs primarily by direct 
conjugation (glucuronidation) and secondary 
route of metabolism is via O-demethylation. 
Metabolism is mediated by atleast five human 
uridine diphosphoglucuronosyltransferase 
(UGT) isozymes as well as CYP2D6 and 
CYP2C19. After administration of a single 
oral dose of radiolabeled arformoterol, 63% 
of the radioactive amount was recovered in 
urine and 11% in feces within 48 h. A total of   
89% of the total radioactive dose was 
recovered within 14 days, with 67% in urine 
and 22% in faeces [11].   
 
Clinical studies  
 
Several clinical studies have been conducted 
with arformoterol tartrate to determine its 
pharmacokinetics and/or pharmacodynamics 
efficacy. Baumgartner et al conducted clinical 
trials on 717 patients with COPD using 
arformoterol tartrate and salmeterol xinafoate 
versus placebo in a 12-week, multicenter, 
double-blind, double-dummy and randomized 
study. All patients, including male and female 
(aged ≥ 35 years), with physician-diagnosed 
COPD received arformoterol (15 µg bid, 25 
µg bid, or 50 µg qid via nebulizer), salmeterol 
(42 µg bid via metered-dose inhaler, MDI), or 
placebo. In the study, patients with moderate 
to severe COPD treated with nebulized 
arformoterol were observed to have 
significant and sustained improvement in 
airways functions and dyspnea compared to 
placebo [13]. 
 
Tashkin et al conducted a clinical study which 
was designed to evaluate the safety and 
efficacy of concomitant treatment with 
nebulized arformoterol 15 µg bid and 
tiotropium 18 µg qid dry powder inhaler (DPI) 
in the treatment of COPD. It was a 2-week, 
prospective, multicenter, randomized, 
modified-blind, and double dummy, parallel 
group study. The results demonstrated mean 
FEV1AUC0-24h improvement from baseline for 
arformoterol (0.10 L) and tiotropium (0.08 L) 
treatment groups and greater for the 
combined therapy (0.22 L). Peak FEV1, peak 
FVC and dyspnea were also improved in 
mono-therapies and greatest with combined 
therapy [14].   
 
Donohue et al performed an open-label, 
multicenter, 52-week trial to predict the 
effects of nebulized arformoterol and 
salmeterol MDI on COPD patients using short 
Pahwa  et al  
Trop J Pharm Res, December 2010; 9(6): 599 
acting bronchodilators. Participants were 
randomized to nebulized arformoterol 50 µg 
dose once daily or salmeterol 42 µg dose 
twice per day. Decrease in albuterol and 
ipratromium use were observed in both 
treatment groups, and remained stable over 
52 weeks. COPD exacerbation frequency 
also did not increase over time [15]. 
 
Kharidia et al conducted a pharmacokinetic/ 
pharmacodynamic study comparing 
nebulized arformoterol 15 µg and racemic 
formoterol DPI (12 and 24 µg) in subjects 
with COPD. It was an open-label, two-week 
randomized, multicenter, multi-dose, three-
way crossover study conducted on 39 
subjects who received study medication twice 
daily, among whom 33 subjects (84.6 %) 
received all treatments and completed the 
trial. In this study, steady-state exposure to 
(R, R)-formoterol in COPD subjects was 
similar following 14 days of administration of 
either 15 µg nebulized arformoterol or 12 µg 
of racemic formoterol DPI and lower than that 
with 24 µg racemic formoterol DPI [16].   
 
Hanrahan et al also performed a double-
blind, 12-week, randomized trial to determine 
the effect of nebulized arformoterol on airway 
function in patients with COPD. Pulmonary 
function efficacy of nebulized arformoterol (15 
µg bid, 25 µg bid, 50 µg qid) and salmeterol 
MDI (42 µg bid) versus placebo was 
assessed in 1456 subjects. The percent 
change in trough FEV1, percent change in 
FEV1 average AUC0-12h and peak percent 
change in FEV1 from pre-dose were 
analyzed. The results demonstrated that 
improvement in trough FEV1 over 12 weeks 
was greater for arformoterol and salmeterol 
versus placebo. Increase in FEV1AUC0-12h 
and peak percent change was also greater 
for arformoterol than for salmeterol. After 12 
weeks study, 78-87 % of arformoterol 
subjects had ≥ 10 % increase in FEV1 from 
pre-dose (56% salmeterol, 44 % placebo). 
Trials demonstrated a significant and 
sustained improvement in lung function over 
12 weeks with COPD subjects on nebulized 
arformoterol [17]. In the same year, the 
authors also undertook two double-blind, 
randomized clinical trials to describe the 
pretreatment arrhythmia occurrence 
frequency in patients with COPD and to 
determine the effects of inhaled long-acting 
β2-agonists such as arformoterol and 
salmeterol.  In this study, 24 h Holter 
monitoring data were pooled from two 
identically designed phase III trials. The 
patients were randomized to LABA treatment 
or placebo for 12 weeks: a) nebulized 
arformoterol 15 µg bid; b) 25 µg bid; or c) 50 
µg qid; d) salmeterol metered dose inhaler 42 
µg bid; or e) placebo. Proportions of 
occurrence of various types of arrhythmias 
such as atrial tachycardia, atrial 
fibrillation/flutter, and nonsustained and 
sustained ventricular tachycardia were 
observed. The results demonstrated that 
atrial tachycardia occurred more frequently 
(41.8 %) than atrial fibrillation/flutter (0.1 %), 
nonsustained ventricular tachycardia (3.1 %), 
and >10 beat ventricular tachycardia (0.3 %) 
[18]. 
 
Lotvall et al, in a randomized double-blind 
crossover study, examined the effect of 
formoterol racemate and enantiomers on 
bronchodilation in 46 patients with reversible 
asthma. Formoterol was inhaled by nebulizer 
(4.5 and 36 µg) as the racemate, (2.25 and 
18 µg) of (R, R)-formoterol, 18 µg of (S, S)-
formoterol or placebo. Airway and systemic 
effects were assessed by serial 
measurement of forced expiratory volume 
(FEV1) and heart rate. The results 
demonstrated that racemate and (R,R)- 
formoterol significantly and dose-dependently 
increased FEV1 and no significant effects 
were observed for (S,S)-formoterol on FEV1 
and heart rate [19]. 
 
These clinical studies indicate that 
arformoterol tartrate provides significant and 
sustained improvement in airways functions 
of patients suffering from moderate to severe 
COPD with fewer side effects and better 
tolerance. These studies also indicate that 
this drug can be a promising candidate for 
COPD therapy and may be administered in 
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nebulized form with sustained duration of 
action.  
 
Analytical techniques, pharmacokinetics 
and compatibility 
 
(R, R)-formoterol and (S, S)-formoterol in 
human plasma have been analyzed using a 
sensitive and robust LC-MS-MS method with 
an Astec chirobiotic T2 column (250 x 2.0 
mm). The mobile phase consisted of 
methanol/acetonitrile/H2O containing 10 mM 
NH4COOH: 78/20/2 (v/v/v) with 0.25 and 
0.006% CH3COOH and NH4OH, respectively. 
The flow rate was 0.2 mL/min and injection 
volume 30 µL. The results showed that there 
was no matrix interference across the elution 
windows of (R,R)-formoterol and (S,S)-
formoterol. The mean (n = 3) correlation 
coefficients in human plasma were 0.9994 ± 
0.0002 and 0.9985 ± 0.0005 for (R, R)-
formoterol and (S, S)-formoterol, respectively. 
Thus, a validated method has been 
successfully employed for the quantification 
of both isomers of formoterol in human 
plasma. No inversion of (R,R)-formoterol to 
(S,S)-formoterol was observed [20]. 
 
The pharmacokinetics of arformoterol tartrate 
inhalation solution in subjects classified as 
poor versus extensive Cytochrome P450 
(CYP) 2D6 metabolizers or with reduced 
uridine diphosphate glycosyltransferase 1 
polypeptide A1 (UGT1A1) activity has been 
characterized. Plasma samples were 
collected up to 168 h post-dose and were 
analyzed by a validated chiral LC/MS/MS 
method. The results indicated that subjects 
with reduced CYP2D6 and/or UGT1A1 
enzyme activity did not exhibit any increase 
in systemic exposure to (R,R)-formoterol 
compared with subjects with normal CYP2D6 
and/or UGT1A1 enzyme activity [21]. 
 
Chemical and physical compatibility of 
arformoterol (15 µg/2mL) with ipratropium 
bromide (0.5 mg/2.5mL), acetylcysteine (800 
mg/4mL), and budesonide (0.25 mg/2mL and 
0.5 mg/2mL) was assessed using visual 
inspection, pH measurement and HPLC 
assay of each active component. The 
findings indicate that there was no visible 
signs of change and the pH of all admixtures 
ranged from 4.82 to 6.40, which was within 
the range of individual drugs. The content of 
each active component in all the admixtures 
ranged from 98.3 to 101.4 %, compared to 
the control thus indicating that the 
acceptance criteria of not more than 10.0 % 
were met [22]. 
 
In another study, human hepatoma cells were 
cultured in the presence of (R,R)-formoterol 
and Na2
35
SO4 to determine whether 
formoterol is metabolized by sulphate 
conjugation. The accumulated radiolabeled 
sulphate conjugates were determined by 
reversed phase HPLC and scintillation 
counting of peaks. Mass spectroscopy 
analysis of individual peaks allowed 
identification of the fragments of formoterol 
sulphate. Separation of the constituents of 
culture medium by reversed phase HPLC 
produced a major peak with a retention time 
of 12 min [10]. 
 
 The levels of (R,R)-formoterol and (S,S)-
formoterol have also been measured using a 
validated chiral analytical method, in 
accordance with the United States Food and 
Drug Administration (USFDA) guidelines. 
Pharmacokinetic parameters for (R,R)- and 
(S,S)-formoterol were also determined by 
non-compartmental methods using WinNonlin 
Professional 5.1.1 (Pharsight, Mountainview, 
CA). The results indicate that in vivo chiral 
inversion did not occur during treatment with 
arformoterol [16]. In yet another work, a 
validated chiral HPLC method was 
successfully applied for the determination of 
formoterol stereoisomers and their inversion 
products in an aqueous matrix stored at 5 – 
70 
0
C up to 3 weeks. Analysis was performed 
on a chiral-AGP column (100 x 4 mm, 5  µm) 
using a variable mixture of mobile phase at a 
flow rate of 1.3 mL/min and UV detection at 
242 nm. All four formoterol stereoisomers 
were adequately resolved with acceptable 
detection. The method showed acceptable 
accuracy (> 88 %), precision (RSD < 8.5 %) 
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and good linearity (r
2 
> 0.9999) over the 
concentration range investigated. No 
significant difference in inversion of the active 
components in racemic (R, R/S, S)-formoterol 
fumarate and the single isomer (R, R)-
arformoterol tartrate drug formulations was 
observed [23]. 
 
Thus, the foregoing indicate that a number of 
advanced analytical techniques such as 
chiral HPLC, LC-MS-MS, reversed phase 
HPLC, etc, can be suitably employed for the 
quantification of arformoterol tartrate. These 
methods have not only facilitated the 
biochemical analysis of the compound but 
also the determination of its pharmacokinetic 




The recommended dose of arformoterol for 
patients with COPD is 15 µg administered 
twice daily (morning and evening) by 
nebulization. It should be administered via a 
standard jet nebulizer connected to an air 
compressor. The solution requires no dilution 
prior to administration [11,12]. However, 
investigational studies also emphasize that 
the choice of nebulizer/compressor system 
can influence the aerosol properties of 
arformoterol inhalation solution and should be 
considered when prescribing nebulized 
medications [24]. 
 
Adverse effects  
 
The adverse effects of arformoterol in 
patients have been attributed to its activity at 
β2 adrenergic receptors, similar to those of 
other β2-agonists. Table 2 summarizes the 
adverse events reported in at least 2 % of 
patients for arformoterol compared with 
placebo in clinical trials. These include 
arrhythmias, atrial tachycardia, pain, chest 
pain, diarrhea, back pain, sinusitis, rashes, 
leg cramps and dyspneoa. Some clinical 
trials also reported other adverse effects such 
as tremors, insomnia and nervousness [11]. 
However, the safety profile of arformoterol 
has been recently documented [25,26]. 
 
Table 2: Adverse effects of arformoterol and 









Lung disorders 2  1  
Peripheral 
edema 
3  2  
Flu syndrome 3  1  
Rashes 4  2  
Dyspnea 4  2  
Leg cramps 4  2  
Sinusitis 5  4  
Diarrheoa 6  4  
Pain 8  5  
Chest pain 7  6  
Back pain  6  2  
 
Drug interactions and contraindications  
 
Some findings regarding drug interactions 
and contraindications of arformoterol are 
summarized below [12]: 
• No pharmacokinetic drug interactions 
were observed with co-administration of 
paroxetine, a potent CYP2D6 inhibitor. 
• Arformoterol and β-blockers should 
generally not be used concomitantly. β-
blockers may interfere with the effects of 
β-agonists and produce severe 
bronchospasm in COPD patients. 
• Co-administration with methylxanthines, 
steroids or diuretics may potentiate the 
hypokalemia observed with adrenergic 
agonists. 
• Arformoterol should be administered with 
caution in patients receiving concomitant 
monoamine oxidase inhibitors, tricyclic 
antidepressants, or drugs which prolong 
the QTc interval because of increased 
adverse cardiovascular effects.  
• Arformoterol is contraindicated in patients 
with a history of hypersensitivity to 
arformoterol, racemic formoterol or any of 
the product ingredients. 
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• Co-administration with other adrenergic 
agents by any route should be done with 





Bronchodilators hold a central role in the 
symptomatic management of COPD and 
asthma. Significant clinical characteristics of 
arformoterol and current analytical 
methodologies for its determination have 
been discussed. Arformoterol has emerged 
as one of the promising and efficacious drug 
in bronchospasm and is a selective β2 
adrenergic agonist with long acting 
bronchodilator activity. Compared to other 
agents, the pharmacological properties and 
therapeutic efficacy of this drug appear to be 
significant. Due to its enhanced clinical 
efficacy, favourable dosage, pharmacokinetic 
profile and tolerability, it is an excellent 
candidate for further investigation of the 
newer indications of COPD and as an 
alternative to dry powder inhalers. However, 
further scientific and technological 
advancements in pharmacology, clinical 
studies and analytical techniques are 
required to optimally harness the therapeutic 
benefits of the drug as well as its appropriate 
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